Trial-level association between response-based endpoints (RBEs) and progression-free (PFS)/overall survival (OS) in first-line therapy for metastatic colorectal cancer (mCRC) in the ARCAD database. (2015)
- Authors:
- Coart, Elisabeth
- Saad, Everardo D.
- Shi, Qian
- Sommeijer, Dirkje Willemien
- Zalcberg, John Raymond
- Maughan, Tim
- Goldberg, Richard M.
- Schmoll, Hans-Joachim
- Punt, Cornelis J. A.
- Cutsem, Eric Van
- Douillard, Jean-Yves
- Hoff, Paulo Marcelo
- Tebbutt, Niall C.
- Fuchs, Charles S.
- Falcone, Alfredo
- Tournigand, Christophe
- De Gramont, Aimery
- Sargent, Daniel J.
- Burzykowski, Tomasz
- Buyse, Marc E.
- Autor USP: HOFF, PAULO MARCELO GEHM - FM
- Unidade: FM
- DOI: 10.1200/jco.2015.33.3_suppl.666
- Subjects: TAXA DE SOBREVIVÊNCIA; NEOPLASIAS COLORRETAIS; METÁSTASE NEOPLÁSICA
- Language: Inglês
- Imprenta:
- Publisher place: Philadelphia
- Date published: 2015
- Source:
- Título: Journal of Clinical Oncology
- ISSN: 0732-183X
- Volume/Número/Paginação/Ano: v. 33, n. 3S , abstr. 666, 2015
- Conference titles: Gastrointestinal Cancers Symposium
- Este periódico é de acesso aberto
- Este artigo NÃO é de acesso aberto
-
ABNT
COART, Elisabeth et al. Trial-level association between response-based endpoints (RBEs) and progression-free (PFS)/overall survival (OS) in first-line therapy for metastatic colorectal cancer (mCRC) in the ARCAD database. Journal of Clinical Oncology. Philadelphia: Faculdade de Medicina, Universidade de São Paulo. Disponível em: https://doi.org/10.1200/jco.2015.33.3_suppl.666. Acesso em: 28 jan. 2026. , 2015 -
APA
Coart, E., Saad, E. D., Shi, Q., Sommeijer, D. W., Zalcberg, J. R., Maughan, T., et al. (2015). Trial-level association between response-based endpoints (RBEs) and progression-free (PFS)/overall survival (OS) in first-line therapy for metastatic colorectal cancer (mCRC) in the ARCAD database. Journal of Clinical Oncology. Philadelphia: Faculdade de Medicina, Universidade de São Paulo. doi:10.1200/jco.2015.33.3_suppl.666 -
NLM
Coart E, Saad ED, Shi Q, Sommeijer DW, Zalcberg JR, Maughan T, Goldberg RM, Schmoll H-J, Punt CJA, Cutsem EV, Douillard J-Y, Hoff PM, Tebbutt NC, Fuchs CS, Falcone A, Tournigand C, De Gramont A, Sargent DJ, Burzykowski T, Buyse ME. Trial-level association between response-based endpoints (RBEs) and progression-free (PFS)/overall survival (OS) in first-line therapy for metastatic colorectal cancer (mCRC) in the ARCAD database. [Internet]. Journal of Clinical Oncology. 2015 ; 33( 3S ):[citado 2026 jan. 28 ] Available from: https://doi.org/10.1200/jco.2015.33.3_suppl.666 -
Vancouver
Coart E, Saad ED, Shi Q, Sommeijer DW, Zalcberg JR, Maughan T, Goldberg RM, Schmoll H-J, Punt CJA, Cutsem EV, Douillard J-Y, Hoff PM, Tebbutt NC, Fuchs CS, Falcone A, Tournigand C, De Gramont A, Sargent DJ, Burzykowski T, Buyse ME. Trial-level association between response-based endpoints (RBEs) and progression-free (PFS)/overall survival (OS) in first-line therapy for metastatic colorectal cancer (mCRC) in the ARCAD database. [Internet]. Journal of Clinical Oncology. 2015 ; 33( 3S ):[citado 2026 jan. 28 ] Available from: https://doi.org/10.1200/jco.2015.33.3_suppl.666 - Venous thromboembolism and cancer: a systematic review
- A multicenter, multinational analysis of mitomycin C in refractory metastatic colorectal cancer
- Antiangiogenic Drugs for Colorectal Cancer: Exploring New Possibilities
- Reversible serum carcinoembriogenic antigen (CEA) elevation due to orlistat use [Carta]: a case report
- Second-Line Treatment for Advanced Pancreatic Adenocarcinoma: Is There a Role for Gemcitabine?
- GIST retal em uso de imatinibe neoadjuvante com excelente resposta: relato de caso
- Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury
- Estudo retrospectivo de prevalência de instabilidade de microssatélite em pacientes com câncer colorretal (CCR) não selecionados submetidos a cirurgia do tumor primário: análise de 212 pacientes do Instituto do Câncer do Estado de São Paulo - ICESP
- Palliative chemotherapy outcomes in patients with ECOG-PS higher than 1
- Pembrolizumab for metastatic adrenocortical carcinoma with high mutational burden Two case reports
Informações sobre o DOI: 10.1200/jco.2015.33.3_suppl.666 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
